TherapeuticsMD, Inc. (TXMD) Institutional Ownership

Ownership Summary

TherapeuticsMD, Inc. (NASDAQ:TXMD) has 43 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 31.1% of TherapeuticsMD's outstanding shares in December 2025, up from 28.6% in September 2025.
• Their total shares held in TXMD increased 9.62% from the prior quarter, while the number of investors in TherapeuticsMD increased 4.88% year over year.
• Of these 43 funds, 11 grew their exposure to TherapeuticsMD, 10 cut back, and 22 maintained positions.
• Altogether, these fund groups held 3.59Mn shares in TXMD by December 2025, up by 315.5K shares quarter on quarter, and down 68.3K shares year over year.
• Rubric Capital Management LP leads ownership in TXMD with 1.19Mn shares as of December 31, 2025, equal to 10.3% of outstanding shares.
• The largest buyers of TherapeuticsMD for the quarter ending December 2025 were ADAR1 Capital Management, LLC (209.21K), RENAISSANCE TECHNOLOGIES LLC (61.0K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (35.16K), VANGUARD GROUP INC (20.23K), OSAIC HOLDINGS, INC. (8.4K).
• Top sellers of TXMD stock for the quarter ending December 2025 included BRIDGEWAY CAPITAL MANAGEMENT, LLC (17.0K), CITADEL ADVISORS LLC (6.03K), GEODE CAPITAL MANAGEMENT, LLC (2.98K), Morgan Stanley (1.36K), Jpmorgan Chase & Co (293).
• TherapeuticsMD's 10 largest shareholders as of December 2025 include Rubric Capital Management LP (1.19Mn), Clearline Capital LP (635.22K), ADAR1 Capital Management, LLC (418.42K), VANGUARD GROUP INC (397.06K), Tejara Capital Ltd (350.85K), Morgan Stanley (129.22K), BlackRock, Inc. (116.13K), GEODE CAPITAL MANAGEMENT, LLC (106.1K), RENAISSANCE TECHNOLOGIES LLC (96.5K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (35.16K) per Business Quant data.